What started as a futuristic foray into hypercar territory has become a staple among auto-lovers worldwide, but how did the ...

“2024 was a transformative year for Disc, marked by the achievement of several milestones, most notably opening the door to a potential accelerated approval for bitopertin based on Phase 2 ...

TD Cowen initiated coverage of Disc Medicine (IRON) with a Buy rating and no price target The shares are pricing in an opportunity for bitopertin that assumes a modest penetration of the “low ...